Skip to content

Henry Schein HSIC Common stock, shares authorized (in shares)

Common stock, shares authorized (in shares) at other companies

Cardinal Health logo
Cardinal HealthCAH
Solventum logo
SolventumSOLV
Tenet Healthcare logo
Tenet HealthcareTHC
Fortive logo
FortiveFTV
Globus Medical logo
Globus MedicalGMED
Baxter International logo
Baxter InternationalBAX

Other financials

Income statement

See full
Revenue$3.4B+6.3%
Gross profit$1.1B+7.0%
Operating income$182.0M+4.0%
Net income$107.0M-2.7%
EPS (diluted)$0.92+4.5%

Balance sheet

See full
Cash & equivalents$138.0M+8.7%
Total debt$3.7B+17.2%
Total equity$3.3B-1.3%
Total assets$11.3B+7.9%

Cash flow

See full
Operating cash flow-$97.0M-362%
CapEx$25.0M-19.4%
Free cash flow-$122.0M-2,133%

Valuation

See full
Market cap$9.1B-0.6%
Enterprise value$12.69B+4.2%
P/E23.1×+0.5×
P/S0.7×0.0×

Profitability

See full
Gross margin31.2%-0.4pp
Operating margin4.9%-0.2pp
Net margin3%-0.3pp
FCF margin3.3%-1.0pp

Returns & leverage

See full
Return on equity12%+0.2pp
Debt / equity1.1×+0.2×
Current ratio1.4×0.0×

Where this comes from

Reported directly by Henry Schein in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.

The official record: Henry Schein’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Henry Schein's common stock, shares authorized (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Henry Schein's common stock, shares authorized (in shares)?
Henry Schein (HSIC) reported common stock, shares authorized (in shares) of $480M in Q1 2026.
How has Henry Schein's common stock, shares authorized (in shares) changed year-over-year?
Henry Schein's common stock, shares authorized (in shares) decreased by 0.0% year-over-year, from $480M to $480M.
What is the long-term trend for Henry Schein's common stock, shares authorized (in shares)?
Over 5 years (2020 to 2025), Henry Schein's common stock, shares authorized (in shares) has grown at a 0.0% compound annual growth rate (CAGR), from $480M to $480M.